Combination therapy of hybrid cells with BCG injection for treating Cancer Patients

Abstract

The present invention relates to cancer treatment compositions and methods for a specific cancer patient population. In particular, the application describes methods of treating a patient with cancer, such as a neuroblastoma, with a hybrid cell preparation in combination with Mycobacterium bovis bacillus Calmette-Guerin (BCG).

1 . A method for treating a patient with cancer comprising co-administering to a patient in need thereof a composition comprising a primary tumor cell fused to a dendritic cell, and  Mycobacterium bovis  bacillus Calmette-Guerin (BCG), wherein the BCG is not mixed with the hybrid cell composition. 
   
   
       2 . The method of  claim 1 , wherein the BCG is not mixed with the hybrid cell composition. 
   
   
       3 . The method of  claim 1 , wherein the patient has stage I, stage II, stage III, or stage IV cancer, wherein the cancer is according to the American Joint Committee on Cancer (AJCC) 2002 Staging System. 
   
   
       4 . The method of  claim 3 , wherein the patient has stage IV cancer. 
   
   
       5 . The method of  claim 3 , wherein the patient has a cancer selected from the group consisting of renal cancer, ovarian cancer, lung cancer, breast cancer, prostate cancer, bladder cancer, colon cancer, skin cancer and neuroblastoma. 
   
   
       6 . The method of  claim 5 , wherein the patient has neuroblastoma. 
   
   
       7 . The method of  claim 1 , wherein the patient has no evidence of disease following surgery, radiation, chemotherapy, or a combination thereof. 
   
   
       8 . The method of  claim 1 , wherein BCG is administered to the patient after administration of the hybrid cell composition. 
   
   
       9 . The method of  claim 8 , wherein BCG is administered to the patient within about 10 minutes of the administration of the hybrid cell composition. 
   
   
       10 . A method for increasing survival of a patient with cancer, comprising co-administering to a patient in need thereof a composition compris a primary tumor cell fused to a dendritic cell, and  Mycobacterium bovis  bacillus Calmette-Guerin (BCG), 
   
   
       11 . The method of  claim 10 , wherein the BCG is not mixed with the hybrid cell composition. 
   
   
       12 . The method of  claim 11 , wherein the patient has stage IV cancer. 
   
   
       13 . The method of  claim 11 , wherein the patient has a cancer selected from the group consisting of renal cancer, ovarian cancer, lung cancer, breast cancer, prostate cancer, bladder cancer, colon cancer, skin cancer and neuroblastoma. 
   
   
       14 . The method of  claim 13 , wherein the patient has neuroblastoma. 
   
   
       15 . The method of  claim 13 , wherein the patient has no evidence of disease following surgery, radiation, chemotherapy, or a combination thereof. 
   
   
       16 . The method of  claim 10 , wherein BCG is administered to the patient after administration of the hybrid cell composition. 
   
   
       17 . The method of  claim 16 , wherein BCG is administered to the patient within about 10 minutes of the administration of the hybrid cell composition. 
   
   
       18 . A method for stimulating an immune response in a patient with cancer, comprising co-administering to a patient in need thereof a composition compris a primary tumor cell fused to a dendritic cell, and  Mycobacterium bovis  bacillus Calmette-Guerin (BCG), wherein the BCG is not mixed with the hybrid cell composition. 
   
   
       19 . The method of  claim 18 , wherein the patient has stage IV cancer. 
   
   
       20 . The method of  claim 18 , wherein the patient has a cancer selected from the group consisting of renal cancer, ovarian cancer, lung cancer, breast cancer, prostate cancer, bladder cancer, colon cancer, skin cancer and neuroblastoma. 
   
   
       21 . The method of  claim 20 , wherein the patient has neuroblastoma. 
   
   
       22 . The method of  claim 20 , wherein the patient has no evidence of disease following surgery, radiation, chemotherapy, or a combination thereof. 
   
   
       23 . The method of  claim 18 , wherein BCG is administered to the patient after administration of the hybrid cell composition. 
   
   
       24 . The method of  claim 23 , wherein BCG is administered to the patient within about 10 minutes of the administration of the hybrid cell composition.